Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Lymphoma

Free Subscription 10.12.2018 1 Am J Hematol 1 Blood 1 BMC Cancer 5 Br J Haematol 1 J Am Acad Dermatol 1 Lancet Oncol 4 Leuk Lymphoma 1 N Engl J Med

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Hematol

1. CASTELLINO A, Pulido JS, Johnston PB, Ristow KM, et al
   Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
   Am J Hematol. 2018 Dec 5. doi: 10.1002/ajh.25350.
   PubMed     Text format     Abstract available
   
   

   
   Blood

2. MENDEVILLE M, Roemer MGM, van den Hout MFCM, Los-de Vries GT, et al
   Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.
   Blood. 2018 Dec 3. pii: blood-2017-12-822171. doi: 10.1182/blood-2017-12-822171.
   PubMed     Text format    
   
   

   
   BMC Cancer

3. LI W, Blessin NC, Simon R, Kluth M, et al
   Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
   BMC Cancer. 2018;18:1209.
   PubMed     Text format     Abstract available
   
   

   
   Br J Haematol

4. RIVAS-DELGADO A, Magnano L, Moreno-Velazquez M, Garcia O, et al
   Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
   Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15708.
   PubMed     Text format     Abstract available
   
   
5. UMAKANTHAN JM, Iqbal J, Batlevi CL, Bouska A, et al
   Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
   Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15702.
   PubMed     Text format     Abstract available
   
   
6. FRIEDRICHS B, Nickelsen M, Ziepert M, Altmann B, et al
   Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
   Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15710.
   PubMed     Text format     Abstract available
   
   
7. GHOLIHA AR, Hollander P, Hedstrom G, Sundstrom C, et al
   High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.
   Br J Haematol. 2018 Dec 2. doi: 10.1111/bjh.15703.
   PubMed     Text format     Abstract available
   
   
8. HOHLOCH K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, et al
   Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
   Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15712.
   PubMed     Text format     Abstract available
   
   

   
   J Am Acad Dermatol

9. OH SJ, Park JH, Lee JH, Lee DY, et al
   Cutaneous extranodal natural killer/T-cell lymphoma: Clinical implications of whole blood Epstein-Barr virus DNA.
   J Am Acad Dermatol. 2018 Nov 28. pii: S0190-9622(18)32957.
   PubMed     Text format    
   
   

   
   Lancet Oncol

10. LOCKE FL, Ghobadi A, Jacobson CA, Miklos DB, et al
    Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Lancet Oncol. 2018 Nov 30. pii: S1470-2045(18)30864.
    PubMed     Text format     Abstract available
    
    

    
    Leuk Lymphoma

11. KREISSL S, Goergen H, Muller H, Meissner J, et al
    Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1540781.
    PubMed     Text format     Abstract available
    
    
12. MAJOR A, Jackson MW, Smith DE, Kamdar M, et al
    Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1522435.
    PubMed     Text format     Abstract available
    
    
13. RUEDA A, Calvo V, Casanova M, Rodriguez-Abreu D, et al
    Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Leuk Lymphoma. 2018 Dec 5:1-4. doi: 10.1080/10428194.2018.1542147.
    PubMed     Text format    
    
    
14. STEVENSON JKR, Qiao Y, Chan KKW, Beca J, et al
    Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1538509.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

15. SCHUSTER SJ, Bishop MR, Tam CS, Waller EK, et al
    Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: